IQGAP1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the Jurkat human T lymphocyte cell line. This loss-of-function model enables investigation of the scaffold protein IQGAP1 in cytoskeletal dynamics, cell adhesion, and signal transduction. The polyclonal pool, generated via CRISPR/Cas9-mediated gene disruption, mitigates clonal variation and provides a robust tool for functional studies.
The Jurkat cell line is derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. It is a suspension-adapted T lymphocyte model for T cell receptor (TCR) signaling, cytokine production, and apoptosis. With intact proximal TCR signaling and high genetic tractability, Jurkat cells are widely used for knockout studies in immunology and cancer biology.
IQGAP1 operates as a scaffold protein that organizes signal transduction by binding a variety of partners. It stabilizes GTP-bound Rac1 and Cdc42, promoting actin polymerization via Arp2/3 and lamellipodia/filopodia formation. IQGAP1 also interacts with E-cadherin and ??-catenin to regulate adherens junctions and ??-catenin/TCF transcriptional activity. In the MAPK/ERK pathway, it scaffolds MEK and ERK, facilitating ERK1/2 phosphorylation. Upstream, IQGAP1 integrates signals from growth factors (EGF, HGF), TCR engagement, calcium/calmodulin, and integrins, relaying them to mTORC1 and the actin cytoskeleton. Through interactions with CLIP-170, APC, and others, IQGAP1 coordinates migration and adhesion.
In Jurkat T cells, IQGAP1 mediates TCR-induced cytoskeletal reorganization and transcriptional responses. It supports immunological synapse formation and modulates ??-catenin and NFAT localization, linking TCR signals to cytokine production and proliferation. Disrupting IQGAP1 in this leukemic background enables precise dissection of scaffold protein function in T cell receptor signaling, T cell leukemia transformation, and adhesion-mitogenic crosstalk. This model thereby illuminates how IQGAP1 contributes to T cell malignancy and broader immune cell signaling.
Researchers can employ these cells in a variety of assays: Western blotting and RT-qPCR to confirm IQGAP1 ablation and assess changes in phospho-ERK, ??-catenin, and NFAT targets; flow cytometry for TCR-stimulated phospho-ERK and NFAT activation; immunofluorescence to visualize F-actin restructuring. Migration and invasion assays, co-immunoprecipitation of IQGAP1 complexes, and TCR-triggered calcium flux or cytokine secretion measurements further extend utility. Together, these applications support drug target validation and functional genomics screens. For additional technical details, contact Ascent Research.
